# ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 P&L / Income Statement

- Company: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q3 FY2026 10-Q, filed 2026-08-04, accession number 0000879407-26-000057
- Page: https://plicit.ai/financials/arwr/fy2026-q3-income-statement
- Chart image: https://plicit.ai/charts/arwr-fy2026-q3-income-statement-sankey.png

## Chart details: Revenue by Counterparty Name

Income statement for 2026-04-01 through 2026-06-30. View: Counterparty Name. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenue**: 75,253,000 US dollars
- **Total operating expenses**: 245,346,000 US dollars
- **Operating (loss) income**: negative 170,093,000 US dollars
- **Total other (expense) income**: negative 8,812,000 US dollars
- **(Loss) income before income tax expense (benefit) and noncontrolling interest**: negative 178,905,000 US dollars
- **Income tax expense (benefit)**: 11,000 US dollars
- **Net (loss) income including noncontrolling interest**: negative 178,916,000 US dollars
- **Glaxosmithkline Intellectual Property Limited**: 0 US dollars
- **Madrigal**: 25,000,000 US dollars
- **Novartis**: 20,232,000 US dollars
- **Sanofi**: 1,241,000 US dollars
- **Sarepta**: 26,395,000 US dollars
- **Undisclosed (calculated)**: 2,385,000 US dollars
- **Total operating expenses**: 245,346,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to ARROWHEAD PHARMACEUTICALS, INC.: −$194.28 M; to noncontrolling interests: $15.36 M.